CSF1R and colorectal cancer: For example, a phase 1 clinical trial (NCT02777710) evaluated the safety and activity of a tyrosine kinase inhibitor of colony-stimulating factor 1 receptor (CSF1R) (pexidartinib) in combination with anti-PD-L1 antibody (durvalumab) in patients with metastatic/advanced pancreatic or colorectal cancers, and no unexpected events were shown in the group who received the combined therapy [88].